2Goldschlager N, Epstein A E, Naccarlli G, et al. Practical guidelines for clinicians, Who treat patients with amiodarone[J]. Arch Intem Med,2000,160: 1 741. 被引量：1
3Siddoway L A. Amiodarone: Guidelines for use and monitoring[J]. Am Fam physician,2003,68: 2 189. 被引量：1
4Kodana I, Kamiyak, Toyama J.Callular electropharmacology of amiodarone[J].Carodiovascular Research,1997,35: 13. 被引量：1
5Kamiya K, Cheng J,Kodama I,et al. Modulation of repolarizaing Potassium channels and Kv1.5 mRNA by long-term treatment with amiodarone[J]. Circulation,1995,92(S1):373. 被引量：1
6Vitolo E, Tronci M, Larovere MT,et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation[J]. Acta Cardiol, 1981,36: 431. 被引量：1
7Zehender M, Hohnloser S, Müller B,et al.Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation results of a comparative study and a 2-year follow up[J]. J A CC,1992,19: 1 054. 被引量：1
8Kochiadakis GE, Igaumenidis NE, Marketou ME,et al. Low dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation[J]. Am J Cardiol,1998,81:995. 被引量：1
10Donovan KD, Power BM, Hockings BEF, et al. Intravenous flecaimide versus amiodarone for recent-onset atrial fibrillation[J]. Am J Cardiol,1995,75: 693. 被引量：1
